OncoCyte Corporation (OCX): Price and Financial Metrics

OncoCyte Corporation (OCX): $3.14

0.05 (+1.62%)

POWR Rating

Component Grades








OCX Price/Volume Stats

Current price $3.14 52-week high $16.00
Prev. close $3.11 52-week low $3.01
Day low $3.08 Volume 822
Day high $3.15 Avg. volume 18,848
50-day MA $3.50 Dividend yield N/A
200-day MA $5.41 Market Cap 25.88M

OCX Stock Price Chart Interactive Chart >

OCX Stock Summary

  • Of note is the ratio of ONCOCYTE CORP's sales and general administrative expense to its total operating expenses; 99.93% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for ONCOCYTE CORP comes in at -121.99%, a number that bests merely 0.5% of the US stocks we're tracking.
  • In terms of volatility of its share price, OCX is more volatile than 99.12% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to ONCOCYTE CORP, a group of peers worth examining would be ATEX, METX, PWP, CKX, and EXPO.
  • Visit OCX's SEC page to see the company's official filings. To visit the company's web site, go to www.oncocyte.com.

OCX Valuation Summary

  • In comparison to the median Healthcare stock, OCX's price/sales ratio is 470% lower, now standing at -14.8.
  • OCX's EV/EBIT ratio has moved up 33.1 over the prior 94 months.

Below are key valuation metrics over time for OCX.

Stock Date P/S P/B P/E EV/EBIT
OCX 2023-09-22 -14.8 0.6 -0.4 -0.2
OCX 2023-09-21 -14.9 0.6 -0.4 -0.2
OCX 2023-09-20 -15.1 0.6 -0.4 -0.2
OCX 2023-09-19 -15.3 0.6 -0.5 -0.2
OCX 2023-09-18 -15.6 0.6 -0.5 -0.2
OCX 2023-09-15 -14.8 0.6 -0.4 -0.2

OCX Growth Metrics

    Its 2 year price growth rate is now at -59.63%.
  • The 3 year net income to common stockholders growth rate now stands at -344.88%.
  • Its year over year cash and equivalents growth rate is now at -62.46%.
Over the past 33 months, OCX's revenue has gone up $8,097,000.

The table below shows OCX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.097 -42.985 -64.031
2022-06-30 8.064 -42.583 -68.276
2022-03-31 8.027 -39.373 -70.469
2021-12-31 7.727 -35.941 -64.097
2021-09-30 4.641 -35.026 -34.521
2021-06-30 4.212 -30.032 -27.504

OCX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCX has a Quality Grade of F, ranking ahead of 0.09% of graded US stocks.
  • OCX's asset turnover comes in at 0.04 -- ranking 335th of 681 Pharmaceutical Products stocks.
  • ITCI, BHVN, and LFVN are the stocks whose asset turnover ratios are most correlated with OCX.

The table below shows OCX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.040 -0.136 -2.643
2021-03-31 0.030 -0.173 -1.674
2020-12-31 0.021 -0.525 -1.429
2020-09-30 0.013 -0.595 -1.555
2020-06-30 0.003 -2.384 -1.709
2020-03-31 0.000 -9.812 -2.256

OCX Price Target

For more insight on analysts targets of OCX, see our OCX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.67 Average Broker Recommendation 1.4 (Strong Buy)

OncoCyte Corporation (OCX) Company Bio

OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.

OCX Latest News Stream

Event/Time News Detail
Loading, please wait...

OCX Latest Social Stream

Loading social stream, please wait...

View Full OCX Social Stream

Latest OCX News From Around the Web

Below are the latest news stories about ONCOCYTE CORP that investors may wish to consider to help them evaluate OCX as an investment opportunity.

Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference.

Yahoo | September 18, 2023

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C.

Yahoo | September 6, 2023

Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company's VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).

Yahoo | August 28, 2023

Oncocyte Reports Second Quarter 2023 Financial Results

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023.

Yahoo | August 10, 2023

Oncocyte Regains Compliance With Nasdaq Listing Requirements

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Yahoo | August 9, 2023

Read More 'OCX' Stories Here

OCX Price Returns

1-mo N/A
3-mo -26.98%
6-mo N/A
1-year -78.59%
3-year -88.62%
5-year -93.72%
YTD -51.08%
2022 -85.21%
2021 -9.21%
2020 6.22%
2019 63.04%
2018 -70.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!